Event Type and Details:

  • Transcript of Investors' Conference Call for audited standalone and consolidated financial results for Quarter and Financial Year ended March 31, 2026
  • Event held on May 26, 2026
  • Disclosure made under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Management Participants:

  • Mr. Shyam Bhartia, Chairman
  • Mr. Deepak Jain, CEO and Managing Director
  • Mr. Varun Gupta, CFO
  • Mr. Pavleen Taneja, Head Investor Relations

External Analyst Participants during Q&A:

  • Siddharth Gadekar (Equirus)
  • Abhijit Akella (Kotak)
  • Harsh Shah (Rare Enterprises)
  • Archit Joshi (Nuvama)
  • Srishti Jain (Monarch)
  • Nitesh Dhoot (Anand Rathi)

Financial Performance Highlights:

  • Q4 FY26 recorded highest revenue in 14 quarters at ₹1,179 crore, up 12% YoY driven by 10% volume growth
  • EBITDA stood at ₹172 crore, up 11% YoY and 26% QoQ
  • PAT was ₹86 crore, up 17% YoY and 84% QoQ
  • Net debt-to-EBITDA improved to 0.99x with net debt reducing by 11% in FY26
  • Board recommended final dividend of ₹2.5 per share (250%), taking total FY26 dividend to ₹5 per share (500%) with total cash outflow of ₹79.8 crore

Segment-wise Performance:

Specialty Chemicals:

  • Q4 revenue: ₹516 crore, up 6% YoY and 13% QoQ
  • Q4 EBITDA: ₹139 crore with margins at 27% (maintained for 6 consecutive quarters)
  • FY26 revenue: ₹1,937 crore, up 7%; EBITDA: ₹510 crore, up 21%
  • Strong momentum in Pyridine derivatives, Fine Chemicals, and Diketene derivatives

Nutrition Business:

  • Q4 revenue: ₹230 crore, up 21% YoY and 15% QoQ
  • Q4 EBITDA: ₹32 crore, up 42% QoQ with margins at 14%
  • FY26 revenue: ₹790 crore; EBITDA: ₹100 crore
  • Growth driven by volume across segments, led by niacinamide supported by cosmetics demand

Chemical Intermediates:

  • Q4 revenue: ₹433 crore, up 15% YoY and 10% QoQ
  • EBITDA improvement supported by cost pass-through
  • Domestic volumes improved on strong agrochemical and paracetamol demand

Strategic Updates and Pinnacle Journey Progress:

  • Successfully handled Middle East crisis with no force majeure and zero production loss
  • Commissioned Bharuch CDMO plant in record 14 months
  • Completed acquisition of Remidex Pharma to strengthen Human Nutrition premixes portfolio
  • Achieved ₹120 crore lean savings
  • 97th percentile in S&P Global CSA ranking
  • Received WEF Lighthouse Award and successful USFDA audit of Bharuch site
  • Strengthened leadership with key senior hires across departments
  • Transitioned to vertical structure to drive focused growth across nutrition, pharma, agro, cosmetics, industrial and semicon segments

Future Outlook and Guidance:

  • Expect sequential growth in revenue and EBITDA starting Q1 FY27
  • FY27 growth to be led by Specialty Chemicals and Nutrition along with recovery in acetyls
  • Target at least 20% YoY EBITDA growth for FY27
  • Continuing capex investment of ₹400-500 crore yearly, focusing on Gajraula MPP plant
  • CDMO business growing at 30-40% annually with strong pipeline of opportunities
  • 100+ opportunities with approximately ₹3,500 crore potential
  • 20+ confirmed molecules and additional pipeline of 10+ advanced stage molecules with peak potential of ₹1,100 crore

Compliance Statement:

  • Transcript available at: https://www.jubilantingrevia.com/investors/financials/quarterly-results
  • Forward-looking statements disclaimer included in press release and results presentation

Additional Notes Section

  • The document contains the full transcript of the earnings conference call including management presentations and Q&A session with analysts
  • The transcript includes detailed financial performance, strategic updates, and forward-looking guidance